Dec 6, 2012 by Dave Williamson and Brenton FlynnThe Worst of 2012: SynergeticsSynergetics is No. 11 on our list of the very worst healthcare stocks of 2012.
Dec 6, 2012 by Dave Williamson and Brenton FlynnThe Worst of 2012: Assisted Living ConceptsContinuing our countdown of the very worst stocks of 2012 in the health care sector, Assisted Living Concepts comes in at No. 12 on our list.
Dec 6, 2012 by Dave Williamson and Brenton FlynnThe Worst of 2012: DendreonComing in at #13 on our list of the very worst health care stocks of 2012, Dendreon.
Dec 6, 2012 by Dave Williamson and Brenton FlynnThe Worst of 2012: AllscriptsContinuing our countdown of the very worst health care stocks of 2012, at No. 14, Allscripts.
Dec 6, 2012 by Dave Williamson and Max MacalusoNovember Nearly Doubled This Biotech's SharesCelsion is up 71% for November, which is nowhere near what it's done so far year to date.
Dec 5, 2012 by Dave Williamson and Max MacalusoNovember Boosted This Biotech Up 123%This pharmaceutical company's shares more than doubled this month and have more than tripled for the year to date.
Dec 5, 2012 by Dave Williamson and Max MacalusoAnother Unbelievable Month for SareptaSarepta is up another 26% for November, adding to its already staggering YTD gains.
Dec 5, 2012 by Dave WilliamsonIs Peregrine's November Surge a Dead Cat Bounce?Peregrine shot up 81% in November, but don't get too optimistic yet: it's still down 75% from its 52-week high.
Dec 4, 2012 by Dave Williamson and Max MacalusoWhy Dynavax Lost in NovemberHow a recent FDA advisory committee decision cost this company.
Dec 4, 2012 by Dave Williamson and Max MacalusoWhy VIVUS Lost in NovemberThe first obesity drug approved in over a decade hit the market.... to lackluster performance.
Dec 4, 2012 by Dave Williamson and austin smithWhy Supernus Lost in NovemberSupernus raised capital through a dilutive share offering, and share prices suffered as a result.
Dec 4, 2012 by Dave Williamson and Max MacalusoWhy Vertex Lost in NovemberWith the new generation of hepatitis-C drugs delivering incredible cure rates, Vertex's Incivek is getting outpaced.
Dec 4, 2012 by Dave Williamson and Max MacalusoWhy SciClone Lost in NovemberThis U.S.-based seller of licensed drugs in China had a tough quarter.
Nov 30, 2012 by Dave Williamson and Brenton FlynnTeva Guides for DisappointmentTeva's new CEO sets expectations low for this year.
Nov 30, 2012 by Dave Williamson and Brenton FlynnSupernus' Shocking DilutionThe offering caused a sell-off, but is it now safe to jump in?
Nov 30, 2012 by Dave Williamson and Brenton FlynnExelixis' Crowning AchievementAfter 18 long years, Exelixis gets its first FDA approval.
Nov 28, 2012 by Dave WilliamsonSarepta Rumors Drive Shares UpThe whispers about this biotech say it could jump big.
Nov 28, 2012 by Dave WilliamsonIdenix Gets a Big Buy RecThis small biotech just got a major endorsement.
Nov 26, 2012 by Dave Williamson2 Biotech Stocks Attracting SpeculatorsCelsion and Acadia see big pops
